Doctor training aims to boost vaccine rates
NCT ID NCT07651761
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study tests whether training primary care providers on how to talk to patients about vaccines can increase flu and COVID-19 vaccination rates. Over 24,500 patients and their doctors at multiple clinics will take part. Doctors in some clinics will receive special communication training, while others will not. Researchers will then compare vaccination rates between the two groups.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Provider communication training
- What this could lead to
- If successful, this training could help more adults get vaccinated against flu and COVID-19, improving public health.
- What could go wrong
- This is an educational study, not a drug trial. Results depend on how well providers apply the training, and vaccine uptake may not change significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 24,500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria for primary care provider participants are as follows: * Practicing primary care provider at study clinic during the study period * Licensed independent practitioner (MD, DO, NP, PA), including residents Exclusion criteria for primary care provider participants are as follows: * PCPs at participating clinic sites who are members of the investigational team or part of the intervention * PCP participants who practice at more than one study clinic that are assigned to discordant study arms (e.g., control and intervention) will be excluded at the outset of the study. Inclusion criteria for patient participants are specified for each of the two co-primary outcomes as follows: Receipt of the 2026/2027 influenza vaccine, among eligible patients: * Have a qualifying clinic visit, defined as a clinic visit with a study PCP at one of the study clinics during the 2026/2027 influenza vaccine season\* * Have not received the 2026-2027 influenza vaccine prior to the qualifying clinic visit (patients who receive the influenza vaccine on the day of the qualifying study visit are eligible) * Adult (age \>= 18 years) Receipt of the 2026/2027 COVID-19 vaccine, among eligible patients: * Have a qualifying clinic visit, defined as a clinic visit with a study PCP at one of the study clinics during the 2026/2027 COVID-19 vaccine season\* * Have not received the 2026-2027 COVID-19 vaccine prior to the qualifying study visit (patients who receive the COVID-19 vaccine on the day of the qualifying study visit are eligible) * Have at least one risk factor for developing severe COVID-19 according to the CDC, including age \>= 65 years * Adult (age \>= 19 years) Exclusion criteria for patient participants for both co-primary outcomes are the following: * Resident of a state that does not share immunization data with the Massachusetts Immunization Information System (MIIS) For the purposes of this study, the 2026/2027 influenza and COVID-19 vaccine seasons are defined as September 1, 2026, or date the respective vaccine is available (whichever is later) through February 28, 2027. These dates were selected based on the timing of influenza and COVID-19 vaccine administration in prior years according to the Massachusetts immunization for respiratory disease data. This is referred to as the 'study period' elsewhere in the protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID -19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UMass Chan Medical School
Worcester, Massachusetts, 01602, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home antibody tests put to the test: can you read your own COVID-19 result?
- Can lung ultrasound reveal COVID-19's signature in the lungs?
- When the immune system Can't fight back: tracking three respiratory viruses
- Flu's journey: scientists track how influenza passes between people
- The household maze: how does COVID-19 move between family members?
- Can an oral drug stop COVID-19 from turning deadly?